Immunotherapy includes immune checkpoint inhibitors (ICI) such as antibodies targeting
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or the programmed cell death …

RNA-based therapies, and siRNAs in particular, have attractive therapeutic potential for
cancer treatment due to their ability to silence genes that are imperative for tumor …

Lipid nanoparticle (LNP)-mediated nucleic acid therapies, including mRNA protein
replacement and gene editing therapies, hold great potential in treating neurological …

Lipid nanoparticles (LNPs) are currently the most promising clinical nucleic acids drug
delivery vehicles. LNPs prevent the degradation of cargo nucleic acids during blood …

Glioblastoma is one of the most aggressive central nervous system malignancies with high
morbidity and mortality. Current clinical approaches, including surgical resection …

The recent development of RNA‐based therapeutics in delivering nucleic acids for gene
editing and regulating protein translation has led to the effective treatment of various …

Immune checkpoint blockade (ICB) therapy has shown great potential in the treatment of
malignant tumors, but its therapeutic effect on glioblastoma (GBM) is unsatisfactory because …

Gene therapy has shown great potential to treat various diseases by repairing the abnormal
gene function. However, a great challenge in bringing the nucleic acid formulations to the …

Nanomedicine has emerged as a promising platform for disease treatment and much
progress has been achieved in the clinical translation for cancer treatment. Several types of …

Cancer immunotherapy represents a revolutionary strategy, leveraging the patient's immune
system to inhibit tumor growth and alleviate the immunosuppressive effects of the tumor …